American Oriental Bioengineering, Inc., (NYSE: AOB) based in Shenzhen, China, engages in the development, manufacture, and commercialization pharmaceutical and healthcare products.

It offers prescription, over-the-counter (OTC) and nutraceutical products for viral infections, women and children’s health. Its OTC products target bedwetting and incontinence; endometritis, annexitis, and pelvic inflammations; premenstrual syndrome (PMS), and other PMS and menopause-related symptoms; and sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis.

The company’s nutraceutical products include soy peptide products series for overall health. It sells its products primarily to hospitals, clinics, pharmacies, and retail outlets in China.

WHY SHOULD YOU INVEST IN AOBO?

Strong financial performance

• Revenues $US 160,500,000 (Up 45.5%)
• 3Q08 revenue increased 62% to $70 million and with diluted EPS $0.21

Sizeable market opportunity

• An aging population, new drug-delivery technologies, and the need for security packaging will lead the next wave of growth.
• Awarded a High-Tech Status award from the People’s Republic of China in January 2009